Bracco strikes Chinese partnership

Article

The Bracco Group has entered into a joint venture with Sine Pharmaceutical of Shanghai for the production and marketing in China of diagnostic contrast media. The partnership will serve as the springboard for launching this month in China two new

The Bracco Group has entered into a joint venture with Sine Pharmaceutical of Shanghai for the production and marketing in China of diagnostic contrast media. The partnership will serve as the springboard for launching this month in China two new contrast media produced by the Bracco Group, one for MR, the other for ultrasound. Demand for in vivo injectible contrast media in China is growing at more than 20% annually, according to Bracco. The Italian company owns 70% of the new Bracco-Sine joint venture. It has been commercially active in China for about 15 years. A priority of the Bracco Group's Chinese operations is to train local hospital staff and to help consolidate academic ties between Italy and China.

Recent Videos
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.